Metronomic dosing of taxanes for inhibiting tumor growth

Dosage metronomique de taxanes


A metronomic dosing regime for taxanes is provided which inhibits tumor growth in animals.
L'invention concerne un schéma posologique métronomique de taxanes permettant d'inhiber une croissance tumorale chez les animaux.




Download Full PDF Version (Non-Commercial Use)

Patent Citations (3)

    Publication numberPublication dateAssigneeTitle
    WO-0156565-A1August 09, 2001Bristol-Myers Squibb CompanyTaxanes à carbonate en c-4
    WO-0170718-A1September 27, 2001Bristol-Myers Squibb CompanyTaxane anticancer agents
    WO-9853811-A1December 03, 1998Baker Norton Pharmaceuticals, Inc.Methodes et compositions d'administration de taxanes par voie orale a des humains

NO-Patent Citations (3)

    ANONYMOUS: "14th Symposium of the Working Group for Pharmacology in Oncology and Hematology, Bonn, Germany, May 26-27, 2000." INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, vol. 39, no. 2, February 2001 (2001-02), pages 89-92, XP008017652 14th Symposium of the Working Group for Pharmacology in Oncology and Hematology;Bonn, Germany; May 26-27, 2000 ISSN: 0946-1965
    NICOLETTI, ET AL.: "IDN5109, a Taxane with Oral Bioavailability and Potent Antitumor Activity" CANCER RESEARCH, vol. 60, no. 4, 2000, pages 842-846, XP001157549 cited in the application
    POLIZZI, ET AL. : "Oral Efficacy and Bioavailability of a Novel Taxane." CLINICAL CANCER RESEARCH, vol. 6, no. 5, 2000, pages 2070-2074, XP001157550 cited in the application

Cited By (6)

    Publication numberPublication dateAssigneeTitle
    JP-2008540364-ANovember 20, 2008メディゲーネ アクチエンゲゼルシャフトMediGene AGパクリタキセルを含む陽イオン性リポソーム製剤を投与する方法
    JP-2012229255-ANovember 22, 2012Medigene Ag, メディゲーネ アクチエンゲゼルシャフトMediGene AGDosage of cationic liposome containing active ingredient
    US-6750246-B1June 15, 2004Bristol-Myers Squibb CompanyC-4 carbonate taxanes
    US-9233094-B2January 12, 2016Medigene AgMethod of administering a cationic liposomal preparation
    US-9707204-B2July 18, 2017Syncore Biotechnology Co., Ltd.Treatment of breast cancer
    US-9827196-B2November 28, 2017Syncore Biotechnology Co., Ltd.Method of administering a cationic liposomal preparation